• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

With preclinical/clinical transition being the largest failure risk in CNS therapeutics development, join us at HubXchange’s CNS Therapeutics Europe 2021 roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape. Jack Prenderville, Head of Transpharmation Ireland, will be presenting a poster on our latest neuroinflammation studies. Join him between 3.10 – 3.40pm CET, December 2nd, under preclinical discussion.

For more information on this event: https://www.hub-xchange.com/xchanges/


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design